The BioPorto A/S (CPH:BIOPOR) Analysts Have Been Trimming Their Sales Forecasts

The latest analyst coverage could presage a bad day for BioPorto A/S (CPH:BIOPOR), with the analysts making across-the-board cuts to their statutory estimates that might leave shareholders a little shell-shocked. This report focused on revenue estimates, and it looks as though the consensus view of the business has become substantially more conservative.

After the downgrade, the twin analysts covering BioPorto are now predicting revenues of kr.74m in 2021. If met, this would reflect a huge 233% improvement in sales compared to the last 12 months. Before the latest update, the analysts were foreseeing kr.84m of revenue in 2021. It looks like forecasts have become a fair bit less optimistic on BioPorto, given the measurable cut to revenue estimates.

See our latest analysis for BioPorto

Of course, another way to look at these forecasts is to place them into context against the industry itself. It's clear from the latest estimates that BioPorto's rate of growth is expected to accelerate meaningfully, with the forecast 233% revenue growth noticeably faster than its historical growth of 5.5% p.a. over the past five years. Compare this with other companies in the same industry, which are forecast to grow their revenue 22% next year. Factoring in the forecast acceleration in revenue, it's pretty clear that BioPorto is expected to grow much faster than its industry.

The Bottom Line

The clear low-light was that analysts slashing their revenue forecasts for BioPorto next year. Analysts also expect revenues to grow faster than the wider market. Overall, given the drastic downgrade to next year's forecasts, we'd be feeling a little more wary of BioPorto going forwards.

As you can see, the analysts clearly aren't bullish, and there might be good reason for that. We've identified some potential issues with BioPorto's financials, such as major dilution from new stock issuance in the past year. Learn more, and discover the 2 other risks we've identified, for free on our platform here.

Of course, seeing company management invest large sums of money in a stock can be just as useful as knowing whether analysts are downgrading their estimates. So you may also wish to search this free list of stocks that insiders are buying.

If you decide to trade BioPorto, use the lowest-cost* platform that is rated #1 Overall by Barron’s, Interactive Brokers. Trade stocks, options, futures, forex, bonds and funds on 135 markets, all from a single integrated account. Promoted

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
^*Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.